Can tremelimumab be used together with durvalumab?

In the treatment of unresectable hepatocellular carcinoma (uHCC), tremelimumab (tremelimumab)can be combined with blockadePD-L1 antibody drugs are used in combination, such as durvalumab, to achieve better therapeutic effects. They can also be used in combination with platinum-based chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. Texitumumab and durvalumab are immune checkpoint inhibitors with complementary mechanisms of action, which can enhance the effect of T cells on tumor cells and further activate the immune system's ability to attack tumors.